vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $151.7M, roughly 1.2× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs -0.7%, a 8.5% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $21.3M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
AVNS vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $151.7M |
| Net Profit | $-1.3M | $11.8M |
| Gross Margin | 47.5% | 30.4% |
| Operating Margin | 1.4% | 20.4% |
| Net Margin | -0.7% | 7.8% |
| Revenue YoY | 0.7% | -41.1% |
| Net Profit YoY | 99.7% | -80.8% |
| EPS (diluted) | $-0.02 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $151.7M | ||
| Q3 25 | $177.8M | $267.8M | ||
| Q2 25 | $175.0M | $244.0M | ||
| Q1 25 | $167.5M | $211.8M | ||
| Q4 24 | $179.6M | $257.6M | ||
| Q3 24 | $170.4M | $78.8M | ||
| Q2 24 | $171.7M | $76.1M | ||
| Q1 24 | $166.1M | $67.5M |
| Q4 25 | $-1.3M | $11.8M | ||
| Q3 25 | $-1.4M | $55.4M | ||
| Q2 25 | $-76.8M | $-17.7M | ||
| Q1 25 | $6.6M | $21.2M | ||
| Q4 24 | $-397.3M | $61.6M | ||
| Q3 24 | $4.3M | $-8.8M | ||
| Q2 24 | $1.8M | $-364.0K | ||
| Q1 24 | $-900.0K | $-364.0K |
| Q4 25 | 47.5% | 30.4% | ||
| Q3 25 | 48.4% | 57.8% | ||
| Q2 25 | 52.6% | 51.2% | ||
| Q1 25 | 53.6% | 55.9% | ||
| Q4 24 | 54.6% | 55.0% | ||
| Q3 24 | 54.5% | 27.8% | ||
| Q2 24 | 55.7% | 29.7% | ||
| Q1 24 | 57.1% | 15.1% |
| Q4 25 | 1.4% | 20.4% | ||
| Q3 25 | 0.1% | 48.7% | ||
| Q2 25 | -42.6% | 13.8% | ||
| Q1 25 | 6.1% | 38.1% | ||
| Q4 24 | -233.0% | 44.4% | ||
| Q3 24 | 7.0% | 12.3% | ||
| Q2 24 | 3.7% | 7.0% | ||
| Q1 24 | 2.4% | 2.1% |
| Q4 25 | -0.7% | 7.8% | ||
| Q3 25 | -0.8% | 20.7% | ||
| Q2 25 | -43.9% | -7.3% | ||
| Q1 25 | 3.9% | 10.0% | ||
| Q4 24 | -221.2% | 23.9% | ||
| Q3 24 | 2.5% | -11.2% | ||
| Q2 24 | 1.0% | -0.5% | ||
| Q1 24 | -0.5% | -0.5% |
| Q4 25 | $-0.02 | $2.34 | ||
| Q3 25 | $-0.03 | $7.76 | ||
| Q2 25 | $-1.66 | $-2.95 | ||
| Q1 25 | $0.14 | $3.33 | ||
| Q4 24 | $-8.64 | $11.56 | ||
| Q3 24 | $0.09 | $-1.72 | ||
| Q2 24 | $0.04 | $-0.07 | ||
| Q1 24 | $-0.02 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $185.6M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $329.4M |
| Total Assets | $1.1B | $918.5M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $185.6M | ||
| Q3 25 | $70.5M | $166.0M | ||
| Q2 25 | $90.3M | $96.7M | ||
| Q1 25 | $97.0M | $84.7M | ||
| Q4 24 | $107.7M | $40.6M | ||
| Q3 24 | $89.0M | $46.9M | ||
| Q2 24 | $92.2M | $40.8M | ||
| Q1 24 | $75.8M | $30.0M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $329.4M | ||
| Q3 25 | $778.0M | $317.2M | ||
| Q2 25 | $776.3M | $235.3M | ||
| Q1 25 | $839.4M | $176.9M | ||
| Q4 24 | $828.5M | $132.4M | ||
| Q3 24 | $1.2B | $60.4M | ||
| Q2 24 | $1.2B | $62.7M | ||
| Q1 24 | $1.2B | $63.0M |
| Q4 25 | $1.1B | $918.5M | ||
| Q3 25 | $1.1B | $964.5M | ||
| Q2 25 | $1.0B | $841.0M | ||
| Q1 25 | $1.1B | $761.9M | ||
| Q4 24 | $1.2B | $655.3M | ||
| Q3 24 | $1.7B | $438.5M | ||
| Q2 24 | $1.7B | $422.4M | ||
| Q1 24 | $1.7B | $404.3M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $70.4M |
| Free Cash FlowOCF − Capex | $21.3M | $69.0M |
| FCF MarginFCF / Revenue | 11.8% | 45.5% |
| Capex IntensityCapex / Revenue | 3.8% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $70.4M | ||
| Q3 25 | $14.0M | $99.5M | ||
| Q2 25 | $6.8M | $27.3M | ||
| Q1 25 | $25.7M | $51.0M | ||
| Q4 24 | $57.9M | $54.0K | ||
| Q3 24 | $23.0M | $6.8M | ||
| Q2 24 | $27.8M | $13.3M | ||
| Q1 24 | $-8.0M | $3.1M |
| Q4 25 | $21.3M | $69.0M | ||
| Q3 25 | $7.0M | $99.2M | ||
| Q2 25 | $-4.2M | $26.5M | ||
| Q1 25 | $19.0M | $50.9M | ||
| Q4 24 | $53.1M | $-341.0K | ||
| Q3 24 | $20.0M | $6.2M | ||
| Q2 24 | $21.9M | $12.7M | ||
| Q1 24 | $-12.1M | $2.3M |
| Q4 25 | 11.8% | 45.5% | ||
| Q3 25 | 3.9% | 37.0% | ||
| Q2 25 | -2.4% | 10.9% | ||
| Q1 25 | 11.3% | 24.0% | ||
| Q4 24 | 29.6% | -0.1% | ||
| Q3 24 | 11.7% | 7.8% | ||
| Q2 24 | 12.8% | 16.7% | ||
| Q1 24 | -7.3% | 3.4% |
| Q4 25 | 3.8% | 0.9% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.3% | ||
| Q1 25 | 4.0% | 0.0% | ||
| Q4 24 | 2.7% | 0.2% | ||
| Q3 24 | 1.8% | 0.8% | ||
| Q2 24 | 3.4% | 0.7% | ||
| Q1 24 | 2.5% | 1.1% |
| Q4 25 | — | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
